US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Arrowhead Pharmaceuticals Inc.

News headline image
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Host Pulmonary R&D Day
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Earns $10 Million Phase 1 Milestone Payment
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
From Arrowhead Pharmaceuticals Inc.
Via Business Wire
Tickers ARWR